NKTR
$72.22-2.62 (-3.50%)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally.
Recent News
2 Healthcare Stocks to Buy Before They Get Bought Out
Abivax and Nektar Therapeutics are clinical-stage biotech companies that would make attractive buyout targets.
How The Nektar Therapeutics (NKTR) Story Is Shifting Around Rezpeg And Fair Value Estimates
The analyst fair value estimate for Nektar Therapeutics has shifted from US$129.86 to US$136.43 per share, reflecting updated assumptions around the company’s outlook. This change is closely tied to fresh Street work on rezpegaldesleukin in atopic dermatitis and alopecia, where models weigh both the potential for multi billion dollar sales, as well as the clinical and competitive risks. As you read on, you will see how these moving pieces shape the evolving narrative and what to watch next in...
DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls
DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls
Wall Street Analysts See a 77.28% Upside in Nektar (NKTR): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 77.3% in Nektar (NKTR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Company News for Mar 16, 2026
Companies In The News Are: ADBE, META, NKTR, ORKA.